🇨🇦 Canada Country × Condition
breast cancer Clinical Trials in Canada
Active clinical trials for breast cancer with research sites in Canada. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 Phases: Phase 2 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇨🇦 Canada
Active Trials in Canada (5)
NCT04608357
Recruiting
Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients
Enrollment
25 pts
Country
🇨🇦 Canada
Sunnybrook Health Sciences Centre
View Trial → NCT05509751
Recruiting
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
Enrollment
60 pts
Country
🇨🇦 Canada
Martine Puts
View Trial → NCT04050423
Recruiting
Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses
Enrollment
1,200 pts
Country
🇨🇦 Canada
Sunnybrook Health Sciences Centre
View Trial → NCT06251401
Recruiting
Cardiac Rehabilitation for Breast Cancer Survivors
Enrollment
50 pts
Country
🇨🇦 Canada
Women's College Hospital
View Trial → NCT04680442 Phase 2
Recruiting
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Enrollment
130 pts
Country
🇨🇦 Canada
Population Health Research Institut...
View Trial → Frequently Asked Questions
How many breast cancer clinical trials are active in Canada?
There are currently 5 active clinical trials for breast cancer with sites in Canada, of which 5 are actively recruiting patients.
How can I join a breast cancer clinical trial in Canada?
To join a breast cancer clinical trial in Canada, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Canada directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are breast cancer trials in Canada?
Active breast cancer trials in Canada span Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.